Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results
Ascending Dose Trial of FABP5 Inhibitor to Read Out Soon
Research Report
Regenerative Medicine Firm OK'd To Advance Trial in T1D
Cell Pouch Co. Peer Aborts Program Using Like Device
Research Report
New Jersey Pharma Co. Shares Positive Pediatric Study
Research Report
Clean Tech Co. Achieves Record-Breaking Revenue for Exceptional Growth
GMP Production of Exosomes Slated for Later This Year
Research Report
Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases
Clinical-stage biotechnology company Coya Therapeutics Inc.'s (COYA:NASDAQ) regulatory T cell-derived exosome (Treg exosome) program is set to enter Good Manufacturing Production (GMP) late this year, paving the way for an initial clinical study. Find out why one analyst calls the company's work a "potential breakthrough."Biotech Co. Advances AI-Generated Cancer Treatments
Rakovina Therapeutics Inc. (RKV:TSX.V) receives the first synthesized batch of artificial intelligence-generated ATR inhibitor compounds developed in collaboration with Variational AI. Find out why the technology could revolutionize the way we treat cancer.Chen Highlights His Premium Silver, Gold Opportunities for Q2
Even with tariff chaos, asset manager Chen Lin of What is Chen Buying? What is Chen Selling? said he is still bullish in the near term for gold silver. Find out which stocks are his top picks for the coming quarter.PDUFA Date Nearing for New PSVT Drug
Research Report
If approved, commercialization will start mid-year; the biopharma behind the treatment offers a potential return of 1,052%, noted an H.C. Wainwright & Co. report. US$200M Deal Accelerates Phase 3 Gene Therapy for Parkinsons
MeiraGTx Holdings Plc.'s (MGTX:NASDAQ) partnership with Hologen AI secures US$200 million to advance its Phase 3 gene therapy for Parkinson's. With regulatory milestones ahead, here's what's next.Two Use Cases for AI in Healthcare
In both, proprietary software platforms analyze heaps of data, but one focuses on genetics, the other neurology. Learn more about the companies behind the technology.Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients
Research Report
Utah biotech Clene Inc. (CLNN:NASDAQ) recently shared new data, reporting the survival benefit of its CNM-Au8 treatment for ALS patients, according to a D. Boral Capital research note. Biotech Stock Looks Like Is Has a Great Set Up
Contributed Opinion
Technical Analyst Clive Maund explains why he thinks Hemostemix Inc. (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) is an Immediate Strong Buy. Biotech Advancing Pivotal Phase III Breast Cancer Trial
Research Report
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc. 
Streetwise Key Charts
